Parkinson Atypical Rating of Oculometric Patterns Evaluated Routinely
Launched by NEURALIGHT · Sep 11, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
As a part of the study, about 40 subjects will undergo a neurological evaluation including motor and cognitive assessments and a NeuraLight session including oculometric measurements and eye-tracking recordings using a novel software-based platform and an eye-tracking system (Tobii, CE-marked class B approved device). Test duration will be approx. 20 minutes. The oculometric evaluation will occur for at least 50% of the cohort 3 times (at baseline, at 6-months and at 12-month follow-up), and all subjects will be recruited over a period of 9 months. All assessments will be performed during a...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women, age between 40 and 80 years
- • \<5 years since disease diagnosis
- • Normal or corrected vision
- • MOCA score ≥ 20
- • Ability to follow instructions
- • Willing and able to sign an informed consent form Specific
- • PD cohort: Ages 50-80, Hoehn \& Yahr scale 1-3
- • PSP cohort: diagnosed according to actual diagnostic criteria from Höglinger GU et al, 2017.
- • MSA cohort: diagnosed according to actual diagnostic criteria from Wenning et al, 2022.
- Exclusion Criteria:
- • -
About Neuralight
Neuralight is a pioneering clinical trial sponsor focused on advancing innovative therapeutic solutions for neurological disorders. With a commitment to enhancing patient outcomes through cutting-edge research and development, Neuralight leverages state-of-the-art technology and a multidisciplinary approach to drive clinical trials that prioritize safety, efficacy, and patient-centric care. The organization collaborates with leading researchers, healthcare professionals, and regulatory bodies to ensure the highest standards of scientific rigor and ethical practices in its clinical investigations. Through its dedication to transforming the landscape of neurology, Neuralight aims to deliver breakthrough treatments that improve the quality of life for individuals affected by complex neurological conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sevilla, , Spain
Patients applied
Trial Officials
Pablo Mir, MD
Principal Investigator
IBIS (Instituto de Biomedicina de Sevilla), Calle Antonio Maura Montaner, Seville, Spain
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported